References
- Anthony K. (2022). RNA-based therapeutics for neurological diseases. RNA Biol 19:1–11.
- Baeken MW, Yokobayashi Y. (2022). Identification of an ERN1 target site within EGFP mRNA. J Cell Biochem 123:1298–305.
- Bogaert B, Sauvage F, Guagliardo R, et al. (2022). A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs. J Control Release 350:256–70.
- Carrasco MJ, Alishetty S, Alameh MG, et al. (2021). Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun Biol 4:956.
- Cheng X, Lee RJ. (2016). The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev 99:129–37.
- Cheng Q, Wei T, Farbiak L, et al. (2020). Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol 15:313–20.
- Clarke RJ. (2019). Effect of cholesterol on the dipole potential of lipid membranes. Adv Exp Med Biol 1115:135–54.
- Durymanov M, Reineke J. (2018). Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers. Front Pharmacol 9:971.
- Eygeris Y, Gupta M, Kim J, Sahay G. (2022). Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res 55:2–12.
- Forster Iii J, Nandi D, Kulkarni A. (2022). mRNA-carrying lipid nanoparticles that induce lysosomal rupture activate NLRP3 inflammasome and reduce mRNA transfection efficiency. Biomater Sci 10:5566–82.
- Koynova R, Tenchov B. (2011). Recent patents in cationic lipid carriers for delivery of nucleic acids. Recent Pat DNA Gene Seq 5:8–27.
- Larson NR, Hu G, Wei Y, et al. (2022). pH-dependent phase behavior and stability of cationic lipid-mRNA nanoparticles. J Pharm Sci 111:690–8.
- Leventis PA, Grinstein S. (2010). The distribution and function of phosphatidylserine in cellular membranes. Annu Rev Biophys 39:407–27.
- Li M, Li Y, Li S, et al. (2022a). The nano delivery systems and applications of mRNA. Eur J Med Chem 227:113910.
- Li N, Sun Y, Fu Y, Sun K. (2021). RNA drug delivery using biogenic nanovehicles for cancer therapy. Front Pharmacol 12:734443.
- Liu S, Cheng Q, Wei T, et al. (2021). Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat Mater 20:701–10.
- Li Y, Zhuang Q, Tao L, et al. (2022b). Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-κB pathway. Cell Prolif 55:e13291.
- Luo J, Yang H, Song BL. (2020). Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol 21:225–45.
- Lv H, Zhang S, Wang B, et al. (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114:100–9.
- Ramachandran S, Satapathy SR, Dutta T. (2022). Delivery strategies for mRNA vaccines. Pharmaceut Med 36:11–20.
- Ruwizhi N, Aderibigbe BA. (2020). The efficacy of cholesterol-based carriers in drug delivery. Molecules 25:4330.
- Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. (2012). Developing mRNA-vaccine technologies. RNA Biol 9:1319–30.
- Seki H. (2018). Complications with vacuum delivery from a forceps-delivery perspective: Progress toward safe vacuum delivery. J Obstet Gynaecol Res 44:1347–54.
- Simberg D, Weisman S, Talmon Y, Barenholz Y. (2004). DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 21:257–317.
- Tenchov R, Bird R, Curtze AE, Zhou Q. (2021). Lipid nanoparticles─from liposomes to mrna vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15:16982–7015.
- To KKW, Cho WCS. (2021). An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opin Drug Discov 16:1307–17.
- Webb C, Ip S, Bathula NV, et al. (2022). Current status and future perspectives on mRNA drug manufacturing. Mol Pharm 19:1047–58.
- Yanez Arteta M, Kjellman T, Bartesaghi S, et al. (2018). Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc Natl Acad Sci U S A 115:E3351–E3360.
- Zhang S, Xu Y, Wang B, et al. (2004). Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release 100:165–80.
- Zhao X, Ma X, Dupius JH, et al. (2022). Negatively charged phospholipids accelerate the membrane fusion activity of the plant-specific insert domain of an aspartic protease. J Biol Chem 298:101430.